SCHEMBL4099032

SCHEMBL4099032

O=C(O)C1CCN(c2ccnc(-c3ccccn3)c2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.56
CYP2C19 P33261 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.50
NOTUM Q6P988 8/20 0.49
KDM6B O15054 1/20 0.49
KDM4A O75164 1/20 0.49
KDM5C P41229 1/20 0.49
KDM4C Q9H3R0 1/20 0.49
KDM2A Q9Y2K7 1/20 0.49
KDM3A Q9Y4C1 1/20 0.49
PDK2 Q15119 1/20 0.46
NEK2 P51955 2/20 0.45
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
CYP46A1 Q9Y6A2 2/20 0.44
METAP1 P53582 1/20 0.44
USP2 O75604 1/20 0.43
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21552512 0.84 KDM4E (0.56) KDM4ECYP2C19L3MBTL1NOTUMNEK2
SCHEMBL16015734 0.80 HTR1A (0.46) KDM4EL3MBTL1METAP1USP2
SCHEMBL5343628 0.79 KDM4E (0.53) KDM4ECYP2C19NOTUMPDK2NEK2
SCHEMBL4891157 0.79 KDM4E (0.56) KDM4ECYP2C19NOTUMPDK2NEK2
SCHEMBL308530 0.78 L3MBTL1 (0.47) KDM4ECYP2C19L3MBTL1KDM6BKDM4A
SCHEMBL2274636 0.77 KDM4E (0.66) KDM4ECYP2C19L3MBTL1NOTUMHPGD
SCHEMBL15578248 0.76 KDM4E (0.56) KDM4ECYP2C19NOTUMNEK2CYP4F2
SCHEMBL1222301 0.76 NOTUM (0.79) KDM4ECYP2C19L3MBTL1NOTUM
SCHEMBL742952 0.75 ITGB3 (0.60) KDM4ECYP2C19NOTUMNEK2USP2
SCHEMBL17180411 0.74 CYP46A1 (0.76) KDM4ECYP2C19L3MBTL1NOTUMNEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10219730-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2019-03-05 US disclosed
US-20160296147-A1 Redox Polymers THERASENSE, INC. 2016-10-13 US disclosed
US-9320467-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2016-04-26 US disclosed
US-9320467-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2016-04-26 US disclosed
US-20140364710-A1 Redox Polymers THERASENSE, INC. 2014-12-11 US disclosed
US-20140364710-A1 Redox Polymers THERASENSE, INC. 2014-12-11 US disclosed
US-8828204-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2014-09-09 US disclosed
US-8795490-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2014-08-05 US disclosed
US-8795490-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2014-08-05 US disclosed
US-8512534-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2013-08-20 US disclosed
US-20110303537-A1 Redox Polymers ABBOTT DIABETES CARE INC. 2011-12-15 US disclosed
US-7918976-B2 Transition metal complexes with bidentate ligand having an imidazole ring ABBOTT DIABETES CARE INC. (US) 2011-04-05 US disclosed
US-7918976-B2 Transition metal complexes with bidentate ligand having an imidazole ring ABBOTT DIABETES CARE INC. (US) 2011-04-05 US disclosed
US-20100288634-A1 Transition Metal Complexes with Bidentate Ligand Having an Imidazole Ring ABBOTT DIABETES CARE INC. 2010-11-18 US disclosed
US-20100288634-A1 Transition Metal Complexes with Bidentate Ligand Having an Imidazole Ring ABBOTT DIABETES CARE INC. 2010-11-18 US disclosed
US-20090145757-A1 Redox Polymers ABBOTT DIABETES CARE INC. 2009-06-11 US disclosed
US-20090145757-A1 Redox Polymers ABBOTT DIABETES CARE INC. 2009-06-11 US disclosed
US-20090099434-A1 OXYGEN-EFFECT FREE ANALYTE SENSOR ABBOTT DIABETES CARE INC. 2009-04-16 US disclosed
US-20090099434-A1 OXYGEN-EFFECT FREE ANALYTE SENSOR ABBOTT DIABETES CARE INC. 2009-04-16 US disclosed
US-20070007132-A1 Transition metal complexes with bidentate ligand having an imidazole ring ABBOTT DIABETES CARE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099434-A1 OXYGEN-EFFECT FREE ANALYTE SENSOR LPO, TXN2, PRDX5 KDM4E 1493/4885CYP2C19 442/4885L3MBTL1 3476/4885
US-10219730-B2 Redox polymers PPOX, OTC, ME3 KDM4E 2030/4885CYP2C19 1025/4885L3MBTL1 3698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.